Navigation Links
David Barker, Former Illumina CSO, Joins GenVault's Scientific Advisory Board
Date:9/28/2007

CARLSBAD, Calif., Sept. 28 /PRNewswire/ -- GenVault Corporation today announces that industry expert David Barker Ph.D. has joined its Scientific Advisory Board. In his role on the board, Dr. Barker will provide scientific guidance facilitating GenVault's entry into new biosample management markets. Dr. Barker brings more than 20 years experience in life science product commercialization as well as experience in serving on the boards of companies such as NextBio, Cell Biosciences, and Microchip Biotechnologies.

"Dr. Barker's extraordinarily deep understanding of the industry and its future will be extremely valuable as we chart our vision. We are very honored to welcome Dr. Barker as a key member of the GenVault advisory team," said David Wellis, CEO of GenVault

"Well-characterized biological samples and their intelligent storage and retrieval are essential for discovering disease genes and biomarkers. I am pleased to be asked to participate in GenVault's creative solutions for sample management " said Dr. Barker

Dr. Barker's previous product commercialization experience includes senior positions at Illumina as Vice President and Chief Scientific Officer; Amersham Biosciences as Vice President and Chief Science Advisor and Molecular Dynamics as Vice President of Research and Business Development until its acquisition by Amersham Biosciences. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

About GenVault

GenVault is redefining the global standard in biosample workflow and storage solutions for genomic medicine, discovery and identification. The company's room temperature technology reduces costs and empowers its partners to maximize their most valuable assets. As a scalable and reliable alternative to traditional freezers and DNA purification systems, GenVault's dry-state platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. For more information visit us at http://www.genvault.com.

EDITORIAL CONTACTS:

David Wellis, GenVault

(760) 268-5256

dwellis@genvault.com


'/>"/>
SOURCE GenVault Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. David Brooks: Segmented nation looks for solidarity amid IT-powered niches
3. CIO Leadership Series: Rick Davidson, Manpower
4. CIO Leadership Series: David Melbye, Milwaukee Metro Sewerage District
5. CIO Leadership Series: David Cagigal, Alliant Energy
6. Former Fiserv exec to enter Business Hall of Fame
7. UW scientist, former WiCell director found stem cell company
8. Kyron appoints former AMA chairman to board
9. Genzyme sues former Bone Care employees
10. Former astronaut a leader in Wisconsin Spaceport
11. New book from former CDC CEO walks readers through innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):